Equity · Healthcare
COGT
NASDAQCogent Biosciences (COGT)
The line runs 33 USD on 14 September through 31.02 USD on 30 October, on a scale from 26 to 34. Days the market did not trade hold the previous close, flat.
- Market cap
- 5.4B USD
- EPS, diluted, year to Dec 2025
- −2.16 USD
- 52-week range
- 14 USD – 43 USD
- Avg volume
- 134.5K
as of Oct 30, 2026
Have Cogent Biosciences (COGT) insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Cogent Biosciences insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Oct 2025, show no open-market purchase.
Form 4, 90 days to 1 Nov 2026, newest reported trade 27 Aug 2026
Buys 0Sells 1Net sold $1.69MOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 27 Aug 2026 | Morris ArleneDirector | Sell | 45,510 | 1.7M USD |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 27 Aug 2026 | Morris ArleneDirector | Option exercise | 45,510 | 245K USD |
Which funds hold Cogent Biosciences (COGT)?
11 of the 45 institutional funds we track reported a Cogent Biosciences position for the quarter ended 30 Jun 2026 — a combined 261.9M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Added | 996,168 | 38.6M USD | +41.0% |
| Balyasny Asset Management | Held (±25%) | 954,843 | 37.0M USD | +11.5% |
| D. E. Shaw & Co. | Trimmed | 922,479 | 35.7M USD | −50.6% |
| Millennium Management | Held (±25%) | 907,712 | 35.1M USD | −23.9% |
| Citadel Advisors | Trimmed | 849,694 | 32.9M USD | −50.5% |
| Point72 Asset Management | Trimmed | 744,195 | 28.8M USD | −47.3% |
| Marshall Wace | Trimmed | 706,153 | 27.3M USD | −55.9% |
| AQR Capital Management | Added | 294,913 | 11.4M USD | +55.4% |
| Fisher Asset Management | Held (±25%) | 184,875 | 7.2M USD | +10.4% |
| Man Group | Held (±25%) | 167,858 | 6.5M USD | −13.8% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Have members of Congress traded Cogent Biosciences (COGT)?
The most recent congressional trade disclosed in Cogent Biosciences is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Dec 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 39 days |
What has been filed or recorded for Cogent Biosciences (COGT)?
The filings we hold for Cogent Biosciences, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 8 shares | 241 USD notional · <0.001% of shares out |
| 28 Sep 2026 | Fails to deliver | Shares failed to deliver | 34 shares | 1K USD notional · <0.001% of shares out |
| 25 Sep 2026 | Fails to deliver | Shares failed to deliver | 72 shares | 2K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.52 USD | |
| 30 Jun 2026 | Financials | Total assets | 834.5M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 532.4M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.53 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.16 USD | |
| 31 Dec 2025 | Financials | Net income | −328.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.16 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.50 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.53 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.52 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.94 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.52 USD |
Cogent Biosciences (COGT): frequently asked questions
What did Cogent Biosciences shares close at?
Cogent Biosciences closed at 31.02 USD on 30 Oct 2026, down 3.00% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Cogent Biosciences’ market cap?
Cogent Biosciences is worth 5.4B USD by market value as of 30 Oct 2026, which is the share price times the shares on issue from its SEC filings.
Have Cogent Biosciences insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Cogent Biosciences insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Oct 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Cogent Biosciences?
11 of the 45 funds we track reported a Cogent Biosciences position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Balyasny Asset Management and D. E. Shaw & Co. See Funds
Have members of Congress traded Cogent Biosciences?
Yes. 1 trade in Cogent Biosciences appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Cogent Biosciences last report earnings?
Cogent Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.52 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings